MDXH MDxHealth SA Stock Quote

MDXH [NASD]

Healthcare | Diagnostics & Research | Belgium

Index	-	P/E	-	EPS (ttm)	-2.81	Insider Own	-	Shs Outstand	15.60M	Perf Week	1.39%
Market Cap	124.93M	Forward P/E	-	EPS next Y	-2.21	Insider Trans	-	Shs Float	3.99M	Perf Month	-1.23%
Income	-	PEG	-	EPS next Q	-0.47	Inst Own	20.55%	Short Float	0.09%	Perf Quarter	0.13%
Sales	22.24M	P/S	5.62	EPS this Y	-	Inst Trans	-	Short Ratio	0.06	Perf Half Y	-15.86%
Book/sh	1.81	P/B	4.43	EPS next Y	1.80%	ROA	-	Target Price	15.33	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	6.20 - 13.17	Perf YTD	-15.86%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-41.46%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	24.35%	ATR	0.61
Employees	-	Current Ratio	-	Sales Q/Q	34.10%	Oper. Margin	-	RSI (14)	49.93	Volatility	7.34% 6.25%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.01	Prev Close	8.01
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	57.39K	Price	7.71
Recom	1.30	SMA20	2.04%	SMA50	-0.28%	SMA200	-10.18%	Volume	134	Change	-3.75%

May-25-22 04:00PM	MDxHealth Announces Results of its Annual and Extraordinary General Shareholders Meetings and Resignation of Director GlobeNewswire -5.06%
May-19-22 04:00PM	Palmetto GBAs MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer GlobeNewswire
Apr-27-22 04:00PM	MDxHealth Reports Q1-2022 Results GlobeNewswire
Apr-25-22 04:00PM	MDxHealth Announces its Ordinary and Extraordinary General Shareholders Meetings GlobeNewswire
Mar-30-22 04:30PM	MDxHealth to Participate in the 14th Annual Kempen Life Sciences Conference GlobeNewswire -6.64%
Mar-02-22 04:00PM	MDxHealth Reports Financial Year 2021 Results and Provides Outlook and Guidance for 2022 GlobeNewswire
Feb-17-22 04:00PM	MDxHealth to Present Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 2nd GlobeNewswire
Feb-09-22 04:00PM	MDxHealth to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference GlobeNewswire
Dec-10-21 06:01PM	MDxHealth Shareholder Transparency Declaration GlobeNewswire -5.06%
Nov-22-21 05:00PM	MDxHealth Shareholder Transparency Declarations GlobeNewswire
Nov-15-21 05:00PM	MDxHealth Announces Completion of Initial Public Offering of ADSs in the United States GlobeNewswire
Nov-09-21 03:38PM	DLA Piper advises underwriters in MDxHealth SA's IPO of American depository shares PR Newswire -5.31%

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience